Preparation method of double-carrier compound of drunkanin A and application of double-carrier compound in anti-osteoarthritis

Through the F127 hydrogel and PEG-PCL nanomicrobes loaded with ashwacin A, the problems of poor drug solubility and insufficient targeting in the treatment of osteoarthritis were solved, and more efficient bone tissue targets were achieved Effect of regeneration of bones.

CN118903156AActive Publication Date: 2024-11-08PEOPLES HOSPITAL OF CHONGQING BANAN DISTRICT
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410945910.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

The existing treatment methods for osteoarthritis have problems such as poor solubility, low bioavailability and insufficient targeting, resulting in uneven distribution of drugs in the body, making it difficult to effectively inhibit bone destruction and promote bone regeneration.

Method used

F127 hydrogel and PEG-PCL nanomicrobes were used to jointly load ashwacin A to form a dual-carrier complex, which improved its solubility and bioavailability, and reduced non-specific distribution by targeting the inflammatory site of bone tissue.

Benefits of technology

It significantly improves the stability and solubility of ashwacin A, prolongs its circulation time, enhances its targeting ability to bone tissue, significantly reduces the level of inflammatory mediators, effectively inhibits bone destruction and promotes bone regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903156A_ABST
    Figure CN118903156A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of osteoarthritis, in particular to a preparation method of a double-carrier compound of drunkanin A and application of the double-carrier compound in resisting osteoarthritis. The F127 hydrogel and the PEG-PCL nano-micelle are jointly loaded and encapsulated to form the nano-composite, so that the solubility and the bioavailability of the drunkanin A can be improved, and the drunkanin A can more effectively target an inflammation part in a bone tissue. The dual-carrier compound has a remarkable effect on inhibiting bone destruction and promoting bone regeneration, and can play a role by reducing inflammatory cell infiltration in bone marrow and reducing release of inflammatory mediators.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of osteoarthritis, and in particular to a method for preparing a dual-carrier complex of withaferin A and its application in anti-osteoarthritis. Background Art

[0002] Osteoarthritis generally refers to degenerative osteoarthritis. Degenerative osteoarthritis, also known as osteoarthritis, degenerative arthritis, senile arthritis, and hypertrophic arthritis, is a degenerative disease caused by many factors such as aging, obesity, strain, trauma, congenital abnormalities of joints, and joint deformities, resulting in degenerative damage to articular cartilage, reactive hyperplasia of joint margins and subchondral bone. Its main treatment method is to reduce the weight of the joints and excessive large-scale activities to delay the progression of the disease. Obese patients should lose weight and reduce the load on the joints. When there are lesions in the lower limb joints, crutches or canes can be used to reduce the burden on the joints. Physical therapy and appropriate exercise can maintain the range of motion of the joints. If necessary, splints and canes can be used to help control acute symptoms. Anti-inflammatory and analgesic drugs can alleviate or control symptoms, but they should be used with caution after evaluating the patient's risk factors and should not be taken for a long time. Chondroprotective agents such as glucosamine sulfate have the effect of relieving symptoms and improving function. At the same time, long-term use can delay the structural progression of the disease. For advanced cases, if the patient's general condition can tolerate the surgery, artificial joint replacement is a recognized effective method to eliminate pain, correct deformity, and improve function, which can greatly improve the patient's quality of life. Summary of the invention

[0003] The present application provides a method for preparing a dual-carrier complex of withaferin A and its application in anti-osteoarthritis.

[0004] To this end, the embodiments of the present application at least disclose the following technical solutions:

[0005] In a first aspect, the embodiment discloses a method for preparing a dual-carrier complex loaded with withaferin A, comprising:

[0006] Prepare F127 hydrogel solution;

[0007] preparing a micellar solution loaded with withaferin A; and

[0008] The F127 hydrogel solution and the micelle solution loaded with withaferin A were mixed.

[0009] In some embodiments, the preparation step of the F127 hydrogel solution comprises: dissolving F127 powder in ddH 2 In O.

[0010] In some embodiments, the concentration of F127 in the F127 hydrogel solution is 40% (w / v).

[0011] In some embodiments, the preparation steps of the micelle solution loaded with withaferin A include:

[0012] The DMSO solution containing withaferin A, the chloroform solution containing PEG-PCL, and water were mixed to form an emulsion;

[0013] The chloroform was removed by rotary evaporation, and the solution was dialyzed in pure water using a dialysis bag with a molecular cutoff of 14,000 Da to remove DMSO, concentrated by ultrafiltration, and filtered.

[0014] In some embodiments, the concentration of Withaferin A in the DMSO solution containing Withaferin A is 1-10 mg / mL, and the concentration of PEG-PCL in the chloroform solution containing PEG-PCL is 20-30 mg / mL.

[0015] In some embodiments, the volume ratio of the DMSO solution containing withaferin A, the chloroform solution containing PEG-PCL and the water is 1:1.5:20.

[0016] In some embodiments, the concentration of Withaferin A in the Withaferin A-loaded micelle solution is 0.1-0.5 mg / mL.

[0017] In some embodiments, the concentration of Withaferin A in the Withaferin A-loaded micelle solution is 0.34 mg / mL.

[0018] In the second aspect, the examples disclose the use of the dual-carrier complex loaded with withaferin A prepared by the preparation method described in the first aspect in the preparation of an anti-osteoarthritis drug.

[0019] The present application forms a nanocomposite by co-loading and encapsulating withaferin A with F127 hydrogel and PEG-PCL nanomicelles, which can improve the solubility and bioavailability of withaferin A and make it more effectively targeted to the inflammatory sites in bone tissue. The dual-carrier complex has a significant effect in inhibiting bone destruction and promoting bone regeneration, and may play a role by reducing inflammatory cell infiltration in the bone marrow and reducing the release of inflammatory mediators.

[0020] Furthermore, the dual carrier complex also improves the bioavailability of withaferin A in other types of inflammation (such as arthritis and muscle inflammation).

[0021] In addition, the dual-carrier complex can significantly improve the stability and solubility of withaferin A in the body and prolong its circulation time in the body. The dual-carrier complex has excellent targeting, can act more accurately on bone tissue, and reduce the nonspecific distribution of drugs in other tissues.

[0022] Moreover, in various inflammation models, the dual-carrier complex showed strong anti-inflammatory effects and could effectively reduce the levels of inflammatory mediators. The targeting of the dual-carrier complex in different tissues may be different, especially in bone inflammation, while in other inflammations, its targeting effect depends on the inflammatory site and the characteristics of the nanomicelles. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Storage modulus (G') and loss modulus (G") of 20%, 30% and 40% (w / v) F127 hydrogels provided in the examples.

[0024] Figure 2 The average swelling ratios of 20%, 30%, and 40% (w / v) F127 hydrogels provided in the examples.

[0025] Figure 3 The average degradation rates of 20%, 30%, and 40% (w / v) F127 hydrogels provided in the examples.

[0026] Figure 4 These are staining images of SD rat joint tissue sections of the Nomal group, OA-Model group, F127+PEG-PLC group, and F127+PEG-PLC+WithaferinA group provided in the examples. Figure 4 A is HE staining picture. Figure 4 B is the immunofluorescence image. Figure 4 C are Safranin Fast Green and Alixin Blueprint respectively. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical scheme and advantages of the present application clearer, the present application is further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described herein are only used to explain the present application and are not intended to limit the present application. The reagents not described separately in detail in the present application are all conventional reagents and can be obtained from commercial channels; the methods not described in detail are all conventional experimental methods and can be obtained from the prior art.

[0028] F127 hydrogel

[0029] 1. Preparation of F127 hydrogel

[0030] F127 (Cat. No. 60318ES60, Yisheng Biotech (Shanghai) Co., Ltd.), also known as Poloxamer 407, is a multifunctional nonionic surfactant composed of block copolymers of ethylene oxide and propylene oxide. This white powder or granular substance is known for its unique temperature sensitivity. It is liquid at low temperatures and turns into a gel state after heating. Weigh 200 mg, 300 mg, and 400 mg of F127 powder respectively and dissolve them in 1 mL ddH 2 O and fully dissolved at 4°C overnight to obtain 20%, 30%, and 40% (w / v) F127 hydrogels.

[0031] 2. Rheological properties and modulus

[0032] The storage modulus (G') and loss modulus (G") of F127 hydrogels were measured on a DHR-2 rheometer using strain sweep mode in the strain range of 1% to 1000% and a fixed frequency of 1 rad / s.

[0033] like Figure 1 As shown in the figure, the storage modulus (G') and loss modulus (G") of three mass fractions of F127 hydrogels were tested with strain from 0.1% to 1000% using the strain scanning mode of the rheometer. As the strain increases, the G' of the hydrogel continues to decrease, while G" continues to increase. The G' and G" curves will have an intersection, and the structure of the hydrogel reaches a critical state. After the intersection, G" is always greater than G', indicating that the network structure of the hydrogel is destroyed and the hydrogel is in a sol state. The 40% F127 hydrogel has stronger rheological properties due to its higher cross-linking density.

[0034] 3. Analysis of swelling and degradation properties of F127 hydrogel

[0035] Freeze-dry the hydrogel and weigh a certain amount of the hydrogel, marked as M 0 The freeze-dried sample was immersed in deionized water. After reaching swelling equilibrium at 37°C, the water on the surface of the hydrogel was absorbed with absorbent paper and weighed, which was marked as M. 1 The swelling ratio of the hydrogel is S = (M 1 -M 0 ) / M 0 ; Three parallel experiments were performed in each group and the average value was taken.

[0036] The hydrogel was weighed and recorded as W1, then immersed in PBS with pH = 7.4 and placed in a 37°C water bath. The hydrogel samples were taken out every other day, excess salt was removed and dried, and the mass was recorded as W2. The remaining mass ratio of the hydrogel was calculated by the following formula (100% × W 2 / W 1 ) was used to evaluate the degradation behavior of the hydrogel.

[0037] like Figure 2 As shown, the average swelling rates of 20%, 30%, and 40% (w / v) F127 hydrogels are 198.5%, 211.3%, and 258.5%, respectively, and they can absorb water exceeding their own mass. This is because a large number of pores and a large number of hydrogen bonds can lock in moisture very well. As the content of F127 increases from 20% to 40%, the hydrogen bond content continues to increase, causing the swelling rate to continue to increase. This result shows that the hydrogel has excellent water absorption properties, can effectively absorb the exudate of wound tissue, and maintain a moist environment for the wound, which is conducive to the rapid healing of wound tissue.

[0038] like Figure 3 As shown in the figure, the degradation performance test results show that F127 hydrogel has certain degradation characteristics. As the content of F127 increases from 20% to 40%, the hydrogel shows a gradually decreasing degradation rate. 40% F127 can still retain more than 50% of its original weight after 7 days. This is mainly because the increasing amount of F127 increases the cross-linking density, making the three-dimensional network structure of the hydrogel more difficult to destroy, which in turn leads to the slow degradation of the hydrogel.

[0039] Dual-carrier complex loaded with withaferin A and release of withaferin A

[0040] 1. Withaferin A-loaded micelles and dual-carrier complexes loaded with Withaferin A

[0041] The preparation method of micelles loaded with withaferin A includes: dissolving 5 mg of withaferin A (product number W133732-1, Shanghai Baishun Biotechnology Co., Ltd.) in 1 mL of DMSO, adding the solution to 1.5 mL of chloroform solution containing 40 mg of PEG-PCL (polyethylene glycol-polycaprolactone, product number Q-0092061, Xi'an Qiyue Biology), mixing evenly, slowly dropping the solution into 20 mL of ultrapure water under ultrasonic action to form an emulsion, removing the chloroform by rotary evaporation, adding the solution to a dialysis bag with a molecular cutoff of 14000 Da, and dialyzing the solution in pure water for more than 24 hours, during which the dialysate is replaced several times (more than 3 times) to completely remove DMSO, concentrating by ultrafiltration, and removing aggregates by filtration (0.22 μm aqueous phase syringe filter), and storing the product at 4° C. for later use.

[0042] The preparation method of the dual-carrier complex loaded with Withaferin A comprises: firstly, 1 mL of 40% F127 hydrogel solution (40%, w / v) and 0.2 mL of PEG-PCL micelle solution loaded with Withaferin A (5 mg / mL, wherein the concentration of Withaferin A is 0.34 mg / mL) are made into gel, chloroform is removed by rotary evaporation, and the mixture is added into a dialysis bag with a molecular cutoff of 14000 Da and dialyzed in pure water for more than 24 hours, during which the dialysate is replaced several times (more than 3 times) to completely remove DMSO, ultrafiltration and concentration are performed, and aggregates are removed by filtration (0.22 μm aqueous phase syringe filter), and the product is stored at 4° C. for standby use, thereby obtaining the dual-carrier complex loaded with Withaferin A.

[0043] 2. Particle size and potential analysis

[0044] The micelles loaded with withaferin A and the dual-carrier complex suspension loaded with withaferin A were respectively diluted with a small amount of pure water, and then the average particle size, particle size distribution and Zeta potential were determined using a Malvern laser particle size analyzer.

[0045] The results are shown in Table 1. The average particle size of the dual-carrier complex loaded with solaferin A did not increase significantly relative to the micelles loaded with solaferin A, and its particle size distribution was relatively uniform. Its Zeta potential also showed that the stability of the dual-carrier complex loaded with solaferin A did not decrease relative to the micelles loaded with solaferin A.

[0046] Table 1

[0047] Withaferin A-loaded micelles Dual carrier complex loaded with withaferin A Average particle size (nm) 162.59±6.36 168.25±8.20 Particle size PDI 0.11 0.13 Zeta potential (mV) 7.97±0.65 7.98±0.60

[0048] 3. Loading rate of withaferin A

[0049] The content of withaferin A was detected in the dialysate obtained during the preparation of micelles loaded with withaferin A, and the weight percentage of the difference between the amount of withaferin A input and the amount of PEG-PCL input was calculated, which was the loading rate of micelles for withaferin A.

[0050] The content of withaferin A was detected in the dialysate obtained during the preparation of the dual-carrier complex loaded with withaferin A, and the difference between the amount of withaferin A input and the mass percentage of the PEG-PCL and F127 hydrogel input was calculated, which was the loading rate of the dual-carrier complex for withaferin A.

[0051] As shown in Table 1, there is no significant difference between the loading rate of withaferin A by the dual-carrier complex and the loading rate of withaferin A by the micelle.

[0052] Table 1

[0053] Withaferin A-loaded micelles Dual carrier complex loaded with withaferin A Amount of carrier added (mg) 40 40 Load rate (%) 6.80 6.82

[0054] 4. Release of Withaferin A

[0055] The micelles loaded with withaferin A and the solutions of the dual-carrier complex loaded with withaferin A were added to dialysis bags (MWCO = 3500 kDa) and immersed in 37°C, 50 mL of pH 7.4 phosphate buffer. The drug release solution was taken at multiple time intervals, and an equal amount of isothermal release medium was added, and its absorbance was measured. The cumulative drug release rate (%) was calculated using the following formula: t / M 0 × 100%, where M t is the cumulative amount of drug released at time t, M 0 is the initial drug loading amount. Results Within 24 hours, the cumulative release rates of withaferin A from micelles loaded with withaferin A and dual-carrier complex loaded with withaferin A were 60% and 20%, respectively.

[0056] Animal experiments

[0057] 1. Experimental Animals

[0058] Sixty healthy SD rats, half male and half female, weighing (142±20) g, aged 4 to 5 weeks (Experimental Animal Center of Liaoning University of Traditional Chinese Medicine, License No.: scxk2010.0001).

[0059] 2. Construction of arthritis model mice (OA-Model) and group experiments

[0060] Preparation of SD rat arthritis model induced by type II collagen: Freund's complete adjuvant was used to prepare an emulsion with a type II collagen concentration of 2.5 mg / mL, and 100 μL was injected intradermally into the left hind paw of each rat to induce inflammation. Arthritis model mice were obtained after 10 days.

[0061] The experimental groups were divided into Nomal group, OA-Model group, F127+PEG-PLC group and F127+PEG-PLC+WithaferinA group. In the Nomal group, 100 μL of 0.9% saline was injected intradermally into the left hind paw of each normal rat. After 10 consecutive days of injection, no intervention was performed. No intervention was performed on the model rats in the OA-Model group. In the F127+PEG-PLC group, 1.8 mg / kg of body weight of equal weight of F127 hydrogel and PEG-PLC micelles were injected intradermally into the left hind paw of each arthritis model rat daily. In the F127+PEG-PLC+WithaferinA group, 1.8 mg / kg of body weight of equal weight of dual-carrier complex loaded with withaferin A was injected intradermally into the left hind paw of each arthritis model rat daily.

[0062] 3. Tissue section staining

[0063] The knee cartilages of mice in each group were taken and tissue sections were prepared for HE staining, safranin fast green staining, alcian blue staining and immunofluorescence staining.

[0064] The results are as follows Figure 4 As shown, the dual carrier system effectively delivers WithaferinA to the site of cartilage damage, increasing the local concentration of the drug in the target area, thereby reducing the extent of cartilage damage. As a natural product, WithaferinA has been shown to have anti-inflammatory and antioxidant properties, which helps to reduce cartilage inflammatory responses and may promote the regeneration and repair process of chondrocytes. The study also observed that the expression of cartilage markers such as COL2A1, SOX9 and Aggrecan increased significantly after the use of dual carriers to deliver WithaferinA. These markers are important molecules required for chondrocytes to synthesize and maintain cartilage matrix. COL2A1 encodes collagen II, which is a cartilage-specific collagen; SOX9 is a key transcription factor that regulates chondrocyte differentiation and matrix synthesis; Aggrecan is an important sulfated glycosaminoglycan that is essential for the mechanical properties of cartilage. F127 and PEG-PLC as dual carriers combine the advantages of the two carriers, improve the water solubility and stability of WithaferinA, and enhance its bioavailability in vivo. This system can effectively deliver WithaferinA to the site of cartilage damage and continuously release the drug during the treatment process, thereby promoting the regeneration and repair of chondrocytes and accelerating the recovery process of cartilage damage. The use of F127 and PEG-PLC as dual carriers to deliver WithaferinA showed significant effects in treating cartilage damage, as shown by significantly reducing the degree of cartilage damage and increasing the expression of cartilage markers COL2A1, SOX9, and Aggrecan, which proves the effectiveness and potential of dual carriers in improving drug delivery efficiency and promoting cartilage repair.

[0065] The above is only a preferred specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with the technical field within the technical scope disclosed in the present application should be covered within the protection scope of the present application.

Claims

1. A method for preparing a dual-carrier complex loaded with withaferin A, comprising: Prepare F127 hydrogel solution; preparing a micellar solution loaded with withaferin A; as well as The F127 hydrogel solution and the micelle solution loaded with withaferin A were mixed.

2. The preparation method according to claim 1, wherein the steps of preparing the F127 hydrogel solution include: Dissolve F127 powder in ddH2O at low temperature.

3. The preparation method according to claim 2, wherein the concentration of F127 in the F127 hydrogel solution is 40% (w / v).

4. The preparation method according to claim 1, wherein the preparation step of the micelle solution loaded with withaferin A comprises: The DMSO solution containing withaferin A, the chloroform solution containing PEG-PCL, and water were mixed to form an emulsion; The chloroform was removed by rotary evaporation, and the solution was dialyzed in pure water using a dialysis bag with a molecular cutoff of 14,000 Da to remove DMSO, concentrated by ultrafiltration, and filtered.

5. The preparation method according to claim 4, wherein the concentration of Withaferin A in the DMSO solution containing Withaferin A is 1 to 10 mg / mL, and the concentration of PEG-PCL in the chloroform solution containing PEG-PCL is 20 to 30 mg / mL.

6. The preparation method according to claim 4, wherein the volume ratio of the DMSO solution containing withaferin A, the chloroform solution containing PEG-PCL and the water is 1:1.5:

20. 7 . The preparation method according to claim 4 , wherein the concentration of Withaferin A in the micelle solution loaded with Withaferin A is 0.1 to 0.5 mg / mL.

8. The preparation method according to claim 4, wherein the concentration of Withaferin A in the Withaferin A-loaded micelle solution is 0.34 mg / mL.

9. Use of the dual-carrier complex loaded with withaferin A prepared by the preparation method according to any one of claims 1 to 8 in the preparation of anti-osteoarthritis drugs.

Citation Information

Patent Citations

  • Targeted controlled-release anti-arthritis medicinal preparation and preparation method thereof

    CN111617036A